American Association for Cancer Research
15357163mct170421-sup-183098_3_supp_4807697_p9wy34.docx (92.63 MB)

Supplemental information, tables, and figures from Targeting Notch1 and IKKα Enhanced NF-κB Activation in CD133+ Skin Cancer Stem Cells

Download (92.63 MB)
journal contribution
posted on 2023-04-03, 15:01 authored by Xin Xin Quan, Nga Voong Hawk, Weiping Chen, Jamie Coupar, Steven K. Lee, David W. Petersen, Paul S. Meltzer, Andrew Montemarano, Martin Braun, Zhong Chen, Carter Van Waes

1. Supplementary Methods. 2. References. 3. Supplementary Table 1. Characteristics of human primary SCC samples. 4. Supplementary Table 2. Clinical characteristics of tumor samples used in different experimental platforms. 5. Supplemental Table 3. GeneGo analysis summery of top 10 ranked signaling pathways for the stem gene signature of CD133+ hcSCC cancer stem cells. 6. Supplementary Figure 1. Clinical information of human primary cutaneous SCC samples and schematic strategy for isolation of cancer stem cell population and function assays. 7. Supplementary Figure 2. Characteristics of transcriptional profile and the top pathways of differentially expressed genes in CD133+ CSCs population. 8. Supplementary Figure 3. IKKα co-localized with CD133 expression in cSCC tissues.


National Institute on Deafness and Other Communication Disorders



Cancer stem–like cells are hypothesized to be the major tumor-initiating cell population of human cutaneous squamous cell carcinoma (cSCC), but the landscape of molecular alterations underpinning their signaling and cellular phenotypes as drug targets remains undefined. In this study, we developed an experimental pipeline to isolate a highly enriched CD133+CD31−CD45−CD61−CD24− (CD133+) cell population from primary cSCC specimens by flow cytometry. The CD133+ cells show enhanced stem–like phenotypes, which were verified by spheroid and colony formation in vitro and tumor generation in vivo. Gene expression profiling of CD133+/− cells was compared and validated, and differentially expressed gene signatures and top pathways were identified. CD133+ cells expressed a repertoire of stemness and cancer-related genes, including NOTCH and NOTCH1-mediated NF-κB pathway signaling. Other cancer-related genes from WNT, growth factor receptors, PI3K/mTOR, STAT pathways, and chromatin modifiers were also identified. Pharmacologic and genetic targeting of NOTCH1, IKKα, RELA, and RELB modulated NF-κB transactivation, the CD133+ population, and cellular and stemness phenotypes. Immunofluorescent staining confirmed colocalization of CD133+ and IKKα expression in SCC tumor specimens. Our functional, genetic, and pharmacologic studies uncovered a novel linkage between NOTCH1, IKKα, and NF-κB pathway activation in maintaining the CD133+ stem SCC phenotypes. Studies investigating markers of activation and modulators of NOTCH, IKK/NF-κB, and other pathways regulating these cancer stem gene signatures could further accelerate the development of effective therapeutic strategies to treat cSCC recurrence and metastasis. Mol Cancer Ther; 17(9); 2034–48. ©2018 AACR.

Usage metrics

    Molecular Cancer Therapeutics



    Ref. manager